| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $150.2M | -21.9% |
| SG&A Expense | $56.8M | -12.9% |
| Operating Income | -$209.3M | +23.4% |
| Pre-tax Income | -$190.9M | +25.8% |
| Income Tax | $0 | -100.0% |
| Net Income | -$190.9M | +25.9% |
| EPS (Basic) | -$0.87 | +34.1% |
| EPS (Diluted) | -$0.87 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $51.7M | -31.3% |
| Current Assets | $257.7M | -15.0% |
| Total Assets | $415.9M | -24.2% |
| Current Liabilities | $32.5M | -8.5% |
| Total Liabilities | $123.4M | -2.5% |
| Stockholders' Equity | $292.5M | -30.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$149.2M | +25.5% |
| Capital Expenditures | $386K | -44.4% |
| Investing Cash Flow | $95.6M | +26.3% |
| Financing Cash Flow | $30.2M | -74.2% |
| Free Cash Flow | -$149.6M | +25.6% |
| +34.1% |